3 recruiting, 1 completed. 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Autonomous Cortisol Secretion (ACS): new trials by email Literature Review of Autonomous Cortisol Secretion (ACS) trials Research Report on Autonomous Cortisol Secretion (ACS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-03-27 |
| Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 15 | 2026-01-14 | 2026-02-11 |
| SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor SPI-62 dose - Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome | Phase 2 | Completed | Sparrow Pharmaceuticals | 30 | 2023-07-01 | 2026-02-13 |
ACTH Syndrome, Ectopic (3) · Cushing Syndrome (3) · Adrenal Hyperplasia, Congenital (2) · Acth-Independent Macronodular Adrenal Hyperplasia (1) · Adrenal incidentaloma (1) · Insulin Resistance (1) · Weight Loss (1)
Adrenal Gland Diseases (3) · Adrenocortical Hyperfunction (3) · Endocrine System Diseases (3) · Metabolic Diseases (3) · Neoplasms (3) · Nutritional and Metabolic Diseases (3) · Paraneoplastic Endocrine Syndromes (3) · Paraneoplastic Syndromes (3) · Adrenogenital Syndrome (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disorders of Sex Development (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2)
Metyrapone (1) · Osilodrostat (1)
Mayo Clinic (2) · Sparrow Pharmaceuticals (1) · University of Texas Southwestern Medical Center (1)
United States (4) · Romania (1) · United Kingdom (1)
Frank Czerwiec, MD (1) · Irina Bancos, MD (1) · Irina Bancos, MD, MS (1)
K23DK142038 (1)